Semax vs Orexin B
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.
Also: Hypocretin-2, Hcrt-2
Orexin B (hypocretin-2) is the sister peptide of orexin A. Both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. Orexin B is a 28-amino-acid linear peptide that mostly acts through the OX2R receptor, the receptor most tied to narcolepsy. The catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Semax has stronger research evidence (Human Trials) compared to Orexin B (Preclinical).
Detailed Comparison
| Attribute | Semax | Orexin B |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally. | Orexin B binds OX2R about as strongly as orexin A does, but binds OX1R roughly 20 times more weakly, so it behaves as a relatively OX2R-preferring signal. OX2R is the receptor that matters most for staying awake and keeping REM sleep in its place: a broken OX2R gene causes inherited narcolepsy in dogs, and the newest approved narcolepsy drug is an OX2R agonist. Structurally, orexin B is a linear chain without the two disulfide bridges that make orexin A more stable. A 1999 mouse study found that injected orexin B was rapidly degraded in blood and none reached the brain intact, while orexin A crossed easily. That is the main reason human research has focused on orexin A. |
| Common Dosing | 200-600 mcg daily 1-3x daily | No established human dose Not established |
| Administration | Intranasal spray (most common) | Intracerebroventricular or local injection in animal studies |
| Typical Duration | 10-30 days typical | Acute single-dose animal experiments |
| Best Time to Take | Morning or early afternoon | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials. | Orexin B has been studied for almost 30 years, but almost entirely as a research tool in animals and tissue. The 1998 discovery paper in Cell (Sakurai and colleagues) showed both orexins increased food intake when injected into rat brains. Work since then has mapped its role in arousal, feeding, and more recently pain: 2026 mouse research found orexin B acting at OX2R could trigger migraine-like headache pain in male but not female mice. We could not find any published study giving orexin B to humans, by nose or by injection, and no registered clinical trials. If you want the orexin story with actual human data, see orexin A. Orexin B on its own is a preclinical compound with a real biological role and no tested human use. |
Frequently Asked Questions: Semax vs Orexin B
What is the difference between Semax and Orexin B?
Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. Orexin B is a cognitive peptide that orexin b (hypocretin-2) is the sister peptide of orexin a. both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. orexin b is a 28-amino-acid linear peptide that mostly acts through the ox2r receptor, the receptor most tied to narcolepsy. the catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or Orexin B?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while Orexin B is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and Orexin B be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and Orexin B together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.